Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9U83
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,025
Award facts
- Contract value 100% obligated
- $25,024.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,024.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of Dupixent 300 mg/2 ml pen auto-injectors (2 ml). This non-set-aside award is scheduled for completion by January 7, 2026, with performance at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999 comprehensive global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (which operates under the AmerisourceBergen brand), is a major pharmaceutical distributor providing critical medical commodities to federal agencies. The company has demonstrated consistent capability to meet federal procurement requirements through open competition, with its contract portfolio encompassing specialty medications, brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order supports the Defense Health Agency and other government healthcare systems in acquiring Dupixent, a biologic medication commonly used for atopic dermatitis and other immunological conditions.
Quick answers
Who was awarded contract SPE2DR26F9U83?
SPE2DR26F9U83 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26F9U83 worth?
The government has obligated $25,025 on SPE2DR26F9U83.
Is contract SPE2DR26F9U83 an order under another contract?
Yes. SPE2DR26F9U83 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9U83 competed?
The extent of competition for SPE2DR26F9U83 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award